RxDoctor Payments Data

Preeti Desai, MD

Cardiovascular Disease · Conroe, TXNPI 1356589956

Payments from drug & device makers

$106,918in general payments, 2019–2025

Across 778 payments — averaging $137.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$93K
  • Amgen$2K
  • Novartis$2K
  • Abbott$1K
  • Boston Scientific$1K
  • Actelion Pharmaceuticals US, Inc.$900
  • plus $7K from 36 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$13,92799%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,918 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$794,749
Medicare patients
823
Services billed
6,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat37$490,869
EliquisApixaban364$400,604
EntrestoSacubitril/Valsartan126$120,292
XareltoRivaroxaban92$103,890
CamzyosMavacamten13$101,052
Repatha SureclickEvolocumab90$67,375
BrilintaTicagrelor54$37,491
NexletolBempedoic Acid17$14,725
EdarbiAzilsartan Medoxomil20$10,650
VascepaIcosapent Ethyl17$9,286
Nifedipine ErNifedipine197$6,036
Ranolazine ErRanolazine55$5,699
Atorvastatin Calcium449$4,300
Nebivolol Hcl37$3,634
Metoprolol Succinate252$3,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$376$490,86937 claims
PfizerEliquis$147$400,604364 claims
NovartisEntresto$1,941$120,292126 claims
Johnson & JohnsonXarelto$822$103,89092 claims
E.r. Squibb & Sons, L.L.C.Camzyos$841$101,05213 claims
AstraZenecaBrilinta$93,214$37,49154 claims
Esperion Therapeutics, Inc.Nexletol$650$14,72517 claims
Arbor Pharmaceuticals, Inc.Edarbi$54$10,65020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →